WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, fireside chat on Wednesday, March 4, 2026 at 11:50 a.m. ET in Boston, MA2026 Jefferies Biotech on the Beach Summit, hosting meetings o ...

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's prese ...

Core Insights - Ironwood Pharmaceuticals reported its fourth quarter and full year 2025 results, highlighting significant developments in its product LINZESS and the advancement of apraglutide [1][2]. Financial Performance - Total revenue for Q4 2025 was $47.7 million, down from $90.5 million in Q4 2024. For the full year 2025, total revenue was $296.2 million, compared to $351.4 million in 2024 [3][11]. - GAAP net loss for Q4 2025 was $2.3 million, or $(0.01) per share, compared to a net income of $2.3 million, or $0.01 per share, in Q4 2024. For the full year 2025, GAAP net income was $24.0 million, or $0.15 per share, compared to $0.9 million, or $0.01 per share, in 2024 [3][40]. - Adjusted EBITDA for Q4 2025 was $10.9 million, down from $37.3 million in Q4 2024. For the full year 2025, adjusted EBITDA was $138.1 million, compared to $129.4 million in 2024 [3][12]. Product Performance - LINZESS achieved 11% year-over-year demand growth in 2025, treating over 5.7 million unique patients since its launch. However, U.S. net sales for LINZESS were $163.2 million in Q4 2025, a 27% decrease from $223.0 million in Q4 2024, and $864.5 million for the full year 2025, a 6% decrease from $916.3 million in 2024 [2][8][9]. - Total LINZESS prescription demand in Q4 2025 was 63 million capsules, a 13% increase compared to Q4 2024, and 234 million capsules for the full year 2025, an 11% increase compared to 2024 [8][9]. Strategic Initiatives - The company plans to focus on maximizing LINZESS, advancing apraglutide, and delivering sustained profits and cash flows in 2026. The financial guidance for 2026 includes expected U.S. LINZESS net sales of $1.125 - $1.175 billion and adjusted EBITDA exceeding $300 million [2][13]. - Apraglutide is being developed for short bowel syndrome patients dependent on parenteral support, with a Phase 3 clinical trial (STARS-2) expected to initiate in Q2 2026 [8][10]. Corporate Developments - In December 2025, Ironwood entered into a settlement agreement with Ferring International Center S.A., agreeing to pay $12.5 million, with $7.5 million paid in December 2025 and the remaining $5.0 million due by December 31, 2026 [10].

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Accessibility Statement] Skip NavigationROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program conducted i ...

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new biomarker data from a late-breaking poster titled “Nasal foralumab downregulates CSF inflammation and upregulates CSF neuroprotective proteomic pathways which correlate with [F-18]PBR06-PET imaging in na-SPMS with PIRA,” which was presented by investigators from Brigha ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional ...

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 20 ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation. ...

Financial Performance - ImmunityBio reported a 700% year-over-year increase in net product revenue for its lead immunotherapy, ANKTIVA, reaching $113 million [1][4] - The company experienced a net loss of $351.4 million for the year, which was a reduction from 2024 losses, attributed to significant revenue offset and lower administrative expenses [2] Sales and Market Expansion - There was a 750% increase in unit sales volume for ANKTIVA, along with a 20% sequential growth in Q4, indicating strong clinical adoption [1] - ImmunityBio established a global commercial footprint with regulatory authorizations in 33 countries, including the US, UK, EU, and Saudi Arabia [2] Product Development and Partnerships - Saudi Arabia approved ANKTIVA for a second indication, metastatic non-small cell lung cancer, marking its first validation in solid tumors beyond bladder cancer [4] - The company formed partnerships with Accord Healthcare in Europe and BioPharma & Cigalah in the Middle East, and established new subsidiaries in Dublin and Riyadh [4] Strategic Vision - ImmunityBio is advancing a three-year global strategy that positions ANKTIVA as the backbone for its Cancer BioShield platform, targeting various tumor types such as glioblastoma, pancreatic cancer, and lymphoma [4]